tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (XRAY), scPharmaceuticals (SCPH) and CSL (OtherCMXHF)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on DENTSPLY SIRONA (XRAYResearch Report), scPharmaceuticals (SCPHResearch Report) and CSL (CMXHFResearch Report).

DENTSPLY SIRONA (XRAY)

In a report issued on April 11, Jeff Johnson from Robert W. Baird reiterated a Buy rating on DENTSPLY SIRONA, with a price target of $67.00. The company’s shares closed last Tuesday at $48.45, close to its 52-week low of $47.06.

According to TipRanks.com, Johnson is a 5-star analyst with an average return of 24.1% and a 62.9% success rate. Johnson covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Tandem Diabetes Care, and Patterson Companies.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for DENTSPLY SIRONA with a $62.56 average price target, implying a 29.1% upside from current levels. In a report issued on April 5, Evercore ISI also maintained a Buy rating on the stock with a $65.00 price target.

See the top stocks recommended by analysts >>

scPharmaceuticals (SCPH)

In a report issued on April 11, Roanna Ruiz from Leerink Partners maintained a Hold rating on scPharmaceuticals. The company’s shares closed last Tuesday at $4.97.

According to TipRanks.com, Ruiz is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -22.6% and a 29.6% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Xeris Pharmaceuticals, and Atea Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for scPharmaceuticals with a $15.00 average price target.

CSL (CMXHF)

According to TipRanks.com, Deakin-Bell is a 3-star analyst with an average return of 1.6% and a 70.1% success rate. Deakin-Bell covers the Healthcare sector, focusing on stocks such as Mayne Pharma Group Limited, Pro Medicus Limited, and Nanosonics Limited.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for CSL with a $235.66 average price target, representing a 19.3% upside. In a report issued on March 31, CLSA also maintained a Buy rating on the stock with a price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on XRAY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed